Stocktoria
ORAMED PHARMACEUTICALS INC. ORMP
ORAMED PHARMACEUTICALS INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | — | $1.3M | $2.7M | $2.7M | $2.7M | $2.7M | $2.4M | $2.5M | $641,000 |
| Gross profit | $13,000 | — | — | — | — | — | — | — | — | — |
| R&D expense | $6.4M | $6.3M | $9.0M | $27.6M | $21.0M | $10.2M | $13.5M | $12.0M | $10.3M | $7.7M |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | -$24.2M | -$11.8M | -$14.6M | -$13.5M | -$10.8M | -$10.0M |
| Interest expense | — | — | $2.0M | — | — | — | — | — | — | — |
| Income tax | $11.3M | $3.2M | — | $100,000 | — | — | $300,000 | — | $400,000 | $1.3M |
| Net income | $64.0M | -$19.1M | $5.1M | -$36.6M | -$23.0M | -$11.5M | -$14.4M | -$12.7M | -$10.5M | -$11.0M |
| EPS (diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | — | — | — | — | — | — |
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$27.9M | -$21.2M | -$12.4M | -$12.9M | -$14.7M | -$5.8M | $4.7M |
| Free cash flow | -$9.2M | -$8.4M | -$10.5M | -$28.4M | -$21.6M | -$12.5M | -$13.0M | -$14.7M | -$5.8M | $4.6M |
| Cash & equivalents | $45.9M | $54.4M | $9.1M | $40.5M | $77.2M | $19.3M | $3.3M | $5.0M | $4.0M | $3.9M |
| Total assets | $230.9M | $155.3M | $220.6M | $161.6M | $128.0M | $44.6M | $34.7M | $47.4M | $38.7M | $42.8M |
| Shareholders' equity | $199.7M | $146.3M | $163.8M | $151.8M | $116.5M | $32.9M | $19.4M | $31.1M | $19.2M | $26.2M |
Growth · year-over-year · Revenue CAGR 15.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -50.4% | +0.0% | -0.3% | +0.3% | +10.4% | -0.3% | +283.2% | — |
| Net income growth | — | -474.6% | — | — | — | — | — | — | — | — |
| EPS growth | — | -442.9% | — | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | — | — | — | — | -225.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.